Publication:
Antivirulence therapy: type IV pilus as a druggable target for bacterial infections

dc.contributor.coauthorBasaran, Esra
dc.contributor.coauthorAvci, Fatma Gizem
dc.contributor.coauthorOzcan, Aslihan
dc.contributor.coauthorKula, Ceyda
dc.contributor.coauthorHassine, Soumaya Ben Ali
dc.contributor.coauthorOzbek, Pemra
dc.contributor.coauthorAkbulut, Berna Sariyar
dc.contributor.departmentDepartment of Chemical and Biological Engineering
dc.contributor.kuauthorKeskin, Özlem
dc.contributor.schoolcollegeinstituteCollege of Engineering
dc.date.accessioned2025-03-06T20:59:28Z
dc.date.issued2024
dc.description.abstractVirulence is an organism's ability to infect the host and cause disease, and this ability is determined by the presence of virulence factors. The "do not kill, neutralize" strategy used by antivirulence therapies is a novel approach to managing the increasing drug resistance. In this respect, type IV pilus is one druggable target among many virulence factors. The type IV pili (T4P) assembly systems with adaptable and flexible filaments are utilized by numerous pathogens for infection. The current work focuses on druggable targets of T4aP with specific emphasis on Pseudomonas aeruginosa, Neisseria meningitidis, and Neisseria gonorrhoeae. Additionally, available information on potential inhibitor molecules that attenuate T4P activities or impair pilus function and/or assembly in different pathogens is summarized. The structural organization of T4aP suggests that ATPases, pilins, tip-associated adhesins, and peptidases could be considered potential target sites. As the number of high-resolution structures of different T4P systems and the computational power to model T4P machineries increase, the pace in the identification of novel molecules and targets to attenuate the activities of T4P will accelerate. Artificial intelligence, which has already penetrated into our daily lives, will definitely have a prominent role in providing a framework for progress in this area.
dc.description.indexedbyWOS
dc.description.indexedbyScopus
dc.description.publisherscopeInternational
dc.description.sponsoredbyTubitakEuTÜBİTAK
dc.description.sponsorshipSupport from TÜBİTAK 120M225 is kindly acknowledged. AO acknowledges YOK 100/2000. EB acknowledges BIDEB 2211-A.
dc.identifier.doi10.1007/s00044-024-03338-5
dc.identifier.eissn1554-8120
dc.identifier.grantnoTrkiye Bilimsel ve Teknolojik Arascedil;timath;rma Kurumu [120M225];TÜBİTAK [100/2000, BIDEB 2211-A];YOK
dc.identifier.issn1054-2523
dc.identifier.issue2
dc.identifier.quartileQ3
dc.identifier.scopus2-s2.0-85208112875
dc.identifier.urihttps://doi.org/10.1007/s00044-024-03338-5
dc.identifier.urihttps://hdl.handle.net/20.500.14288/27715
dc.identifier.volume34
dc.identifier.wos1347267900001
dc.keywordsAntivirulence
dc.keywordsDruggable target
dc.keywordsPathogens
dc.keywordsTherapeutic agents
dc.keywordsType IV pili
dc.language.isoeng
dc.publisherSpringer
dc.relation.ispartofMedicinal Chemistry Research
dc.subjectChemistry, medicinal
dc.titleAntivirulence therapy: type IV pilus as a druggable target for bacterial infections
dc.typeReview
dc.type.otherEarly access
dspace.entity.typePublication
local.publication.orgunit1College of Engineering
local.publication.orgunit2Department of Chemical and Biological Engineering
relation.isOrgUnitOfPublicationc747a256-6e0c-4969-b1bf-3b9f2f674289
relation.isOrgUnitOfPublication.latestForDiscoveryc747a256-6e0c-4969-b1bf-3b9f2f674289
relation.isParentOrgUnitOfPublication8e756b23-2d4a-4ce8-b1b3-62c794a8c164
relation.isParentOrgUnitOfPublication.latestForDiscovery8e756b23-2d4a-4ce8-b1b3-62c794a8c164

Files